Abstract: The present invention provides Ligand-Drug Conjugates comprising a PEG Unit in a parallel orientation to the Drug Unit. The invention provides inter alia, Ligand-Drug Conjugates (LDCs), methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates are stable in circulation, yet capable of inflicting cell death on targeted cells or inhibiting proliferation of targeted cells once its drug cargo is released in the vicinity or within targeted cells. In principle embodiments, an LDC of the present invention is represented by the structure of Formula I.

Abstract: The present disclosure provides, inter alia, ADCs with charge variant chemical linkers useful in treating various diseases such as cancer and autoimmune disorders.

Abstract: The present invention provides Ligand-Drug Conjugates comprising a PEG Unit in a parallel orientation to the Drug Unit. The invention provides inter alia. Ligand-Drug Conjugates (LDCs), methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates are stable in circulation, yet capable of inflicting cell death on targeted cells or inhibiting proliferation of targeted cells once its drug cargo is released in the vicinity or within targeted cells. In principle embodiments, an LDC of the present invention is represented by the structure of Formula I.

Abstract: The present invention provides Ligand-Drug Conjugates comprising a PEG Unit in a parallel orientation to the Drug Unit. The invention provides inter alia, Ligand-Drug Conjugates (LDCs), methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates are stable in circulation, yet capable of inflicting cell death on targeted cells or inhibiting proliferation of targeted cells once its drug cargo is released in the vicinity or within targeted cells. In principle embodiments, an LDC of the present invention is represented by the structure of Formula I.

Abstract: A cover assembly for a resistance band including one or more sleeves each having a base and an attachment structure, the latter removably securing a respective sleeve in a covering disposition on the resistance band. The base and attachment structure are disposable between open and closed orientations. The covering disposition includes the base, having a padded construction, disposed in overlying relation to an inner surface of the resistance band and the attachment structure, including a plurality of elongated flaps, overlapping one another and collectively disposed in overlying relation to an outer surface of the resistance band, concurrent to being in the closed orientation.

Abstract: A method for a dynamic adapter design pattern is described. The method comprises a series of tour components being selected for a user from a plurality of tour components. This selection may be based on interaction information of a plurality of past participants with the plurality of tour components. A selected tour component, from the plurality of tour components, is received from the user. The series of tour components are adapted in real-time based on the selected component. This adaptation occurs by determining the user's prior interaction with the plurality of tour components, comparing the user's prior interaction and the selected tour component with the interaction information of the plurality of past participants, and modifying the series of tour components based on the comparison.

Abstract: The present invention provides Ligand-Drug Conjugates comprising a PEG Unit in a parallel orientation to the Drug Unit. The invention provides inter alia, Ligand-Drug Conjugates (LDCs), methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates are stable in circulation, yet capable of inflicting cell death on targeted cells or inhibiting proliferation of targeted cells once its drug cargo is released in the vicinity or within targeted cells. In principle embodiments, an LDC of the present invention is represented by the structure of Formula I.

Abstract: A method for a dynamic adapter design pattern is described. The method comprises receiving past participant information regarding a plurality of past participants of a tour. Interaction information regarding the plurality of the past participants' interaction with a plurality of components of the tour is also received. The interaction information is mapped to the plurality of components. Particular user information about a current user is received. In response to receiving the particular user information, a recommended order of components of the tour is determined using the past participant information, particular user information, and the interaction information.

Abstract: A method for a dynamic adapter design pattern is described. The method comprises a series of tour components being selected for a user from a plurality of tour components. This selection may be based on interaction information of a plurality of past participants with the plurality of tour components. A selected tour component, from the plurality of tour components, is received from the user. The series of tour components are adapted in real-time based on the selected component. This adaptation occurs by determining the user's prior interaction with the plurality of tour components, comparing the user's prior interaction and the selected tour component with the interaction information of the plurality of past participants, and modifying the series of tour components based on the comparison.

Abstract: The invention relates to methods for treating a subject by manipulating HER-2 on a cell as well as related products. The methods include methods of treating cancer using fatty acid oxidation inhibitors and HER-2 binding molecules such as antibodies and fragments thereof.

Abstract: The invention relates to methods for treating a subject by manipulating HER-2 on a cell as well as related products. The methods include methods of treating cancer using fatty acid oxidation inhibitors and HER-2 binding molecules such as antibodies and fragments thereof.

Abstract: The invention relates to methods for modulating the immune function through targeting of CLIP molecules as well as gamma delta T cells. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, transplant and cell graft rejection, cancer, bacterial infection, HIV infection, and AIDS, as well as novel methods of diagnosis and of introducing a treatment regimen into a subject.